HUSCAP logo Hokkaido Univ. logo

Hokkaido University Collection of Scholarly and Academic Papers >
薬学研究院  >
雑誌発表論文等  >

Liposomes loaded with a STING pathway ligand, cyclic di-GMP, enhance cancer immunotherapy against metastatic melanoma


manuscript.pdf1.07 MBPDF見る/開く

タイトル: Liposomes loaded with a STING pathway ligand, cyclic di-GMP, enhance cancer immunotherapy against metastatic melanoma
著者: Nakamura, Takashi 著作を一覧する
Miyabe, Hiroko 著作を一覧する
Hyodo, Mamoru 著作を一覧する
Sato, Yusuke 著作を一覧する
Hayakawa, Yoshihiro 著作を一覧する
Harashima, Hideyoshi 著作を一覧する
キーワード: STING
Cancer immunotherapy
発行日: 2015年10月28日
出版者: Elsevier
誌名: Journal of controlled release
巻: 216
開始ページ: 149
終了ページ: 157
出版社 DOI: 10.1016/j.jconrel.2015.08.026
抄録: Malignant melanomas escape immunosurveillance via the loss/down-regulation of MHC-I expression. Natural killer (NK) cells have the potential to function as essential effector cells for eliminating melanomas. Cyclic di-GMP (c-di-GMP), a ligand of the stimulator of interferon genes (STING) signal pathway, can be thought of as a new class of adjuvant against cancer. However, it is yet to be tested, because technologies for delivering c-di-GMP to the cytosol are required. Herein, we report that c-di-GMP efficiently activates NK cells and induces antitumor effects against malignant melanomas when loaded in YSK05 lipid containing liposomes, by assisting in the efficient delivery of c-di-GMP to the cytosol. The intravenous administration of c-di-GMP encapsulated with-in YSK05-liposomes (c-di-GMP/YSK05-Lip) into mice efficiently induced the production of type I interferon (IFN) as well as the activation of NK cells, resulting in a significant antitumor effect in a lung metastasis mouse model using B16-F10. This antitumor effect was dominated by NK cells. The infiltration of NK cells was observed in the lungs with B16-F10 melanomas. These findings indicate that the c-di-GMP/YSK05-Lip induces MHC-I nonrestricted antitumor immunity mediated by NK cells. Consequently, c-di-GMP/YSK05-Lip represents a potentially new adjuvant system for use in immunotherapy against malignant melanomas. (C) 2015 Elsevier B.V. All rights reserved.
Rights: © 2015, Elsevier. This manuscript version is made available under the CC-BY-NC-ND 4.0 license
資料タイプ: article (author version)
出現コレクション:雑誌発表論文等 (Peer-reviewed Journal Articles, etc)

提供者: 中村 孝司


本サイトに関するご意見・お問い合わせは repo at へお願いします。 - 北海道大学